Checkpoint Therapeutics, Inc.

CKPT

Find Out if You Qualify for a Financial Reward by filling out the form below.

Checkpoint Therapeutics, Inc. Form












Stock Fraud Law Center does not share your information with others. There is no cost or obligation for you to submit.

Investigation Details

On December 18, 2023, Checkpoint issued a press release announcing that the U.S. Food and Drug Administration had issued a complete response letter for the cosibelimab biologic license application for the treatment of patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation. According to Checkpoint’s release, “[t]he CRL only cites findings that arose during a multi-sponsor inspection of Checkpoint’s third-party contract manufacturing organization as approvability issues to address in a resubmission.” Checkpoint’s President and Chief Executive Officer stated that “we believe we can address the feedback in a resubmission to enable marketing approval in 2024”.

On this news, Checkpoint’s stock price dropped 44.88%, to close at $1.83 per share on December 18, 2023.

Active Cases

Ticker Symbol Company Name Join Deadline Join
UPS United Parcel Service, Inc. December 09, 2024 Join
EW Edwards Lifesciences Corporation December 13, 2024 Join
TD The Toronto-Dominion Bank December 23, 2024 Join
WOLF Wolfspeed, Inc. January 17, 2025 Join